Sep 17, 2018
ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
Sep 13, 2018
ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
Aug 29, 2018
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
Aug 14, 2018
ProMIS Neurosciences Announces Second Quarter 2018 Results
Jul 31, 2018
ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'
Jun 28, 2018
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
Jun 26, 2018
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
May 11, 2018
ProMIS Neurosciences Announces First Quarter 2018 Results
May 01, 2018
ProMIS Neurosciences Closes $7.2 Million Private Placement
Apr 03, 2018
ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
Mar 20, 2018
ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board
Mar 15, 2018
ProMIS Neurosciences to Present at Upcoming Investor Conferences
Mar 14, 2018
ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results
Mar 07, 2018
ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
Jan 25, 2018
ProMIS Neurosciences to Present at Upcoming Investor Conferences
Jan 22, 2018
ProMIS Neurosciences Issues Response to Recent Market Activity
Dec 04, 2017
ProMIS Neurosciences Announces Trading on OTCQB Venture Market
Oct 11, 2017
ProMIS Neurosciences Provides Third Quarter Update for 2017
Sep 21, 2017
ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare
Sep 13, 2017
ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease